{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:02:55Z","timestamp":1761847375186,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":715,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004702","name":"Baxter","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb\/Sanofi-Aventis"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Otsuka"},{"name":"Boston Scientific"},{"name":"Eli Lilly Co."},{"name":"Daiichi Sankyo, Inc."},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Portola"},{"name":"Accumetrics"},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jcin.2011.05.016","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T01:06:10Z","timestamp":1313543170000},"page":"905-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel"],"prefix":"10.1016","volume":"4","author":[{"given":"Masafumi","family":"Ueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore D.","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tello-Montoliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Seecheran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodlipet","family":"Dharmashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaloo","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald K.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore A.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2011.05.016_bib1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","author":"Angiolillo","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib5","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jcin.2011.05.016_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus) (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2011.05.016_bib7","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/eurheartj\/ehn287","article-title":"A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study","volume":"29","author":"Angiolillo","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2011.05.016_bib8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes mellitUS (OPTIMUS)-3 Trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2011.05.016_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc06-1625","article-title":"Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation","volume":"30","author":"Geisler","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcin.2011.05.016_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1160\/TH08-03-0136","article-title":"Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease","volume":"100","author":"Serebruany","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2011.05.016_bib11","article-title":"Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy","volume":"106","author":"Angiolillo","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2011.05.016_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.vph.2007.05.004","article-title":"Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients","volume":"47","author":"Maiti","year":"2007","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jcin.2011.05.016_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","volume":"53","author":"Jeong","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCINTERVENTIONS.109.880179","volume":"3","author":"Jeong","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2011.05.016_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCINTERVENTIONS.110.949859","article-title":"Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention","volume":"3","author":"Hwang","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2011.05.016_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","volume":"57","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1253\/circj.72.35","article-title":"Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients\u2014clilostazol for diabetic patients in drug-eluting stent (CIDES) trial","volume":"72","author":"Ahn","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2011.05.016_bib18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jacc.2005.07.048","article-title":"Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis","volume":"46","author":"Lee","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib19","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","article-title":"Coronary stent restenosis in patients treated with cilostazol","volume":"112","author":"Douglas","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2011.05.016_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jacc.2007.11.049","volume":"51","author":"Lee","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2011.05.016_bib21","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1161\/CIRCULATIONAHA.108.822791","article-title":"Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"119","author":"Chen","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2011.05.016_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2009.11.014","article-title":"Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)","volume":"159","author":"Lee","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2011.05.016_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ajhp\/58.6.485","article-title":"Treatment of intermittent claudication with pentoxifylline and cilostazol","volume":"58","author":"Tjon","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jcin.2011.05.016_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2011.05.016_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0190-9622(94)70069-9","article-title":"Pentoxifylline","volume":"30","author":"Samlaska","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcin.2011.05.016_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0306-3623(93)90218-M","article-title":"Antiplatelet effect of pentoxifylline in human whole blood","volume":"24","author":"de la Cruz","year":"1993","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.jcin.2011.05.016_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"10.1016\/j.jcin.2011.05.016_bib28","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/0006-2952(88)90632-6","article-title":"Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin","volume":"37","author":"Rossignol","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jcin.2011.05.016_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejphar.2007.11.054","article-title":"Effect of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans","volume":"581","author":"Magnusson","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcin.2011.05.016_bib30","first-page":"254","article-title":"Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor","volume":"112","author":"Hammerschmidt","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jcin.2011.05.016_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcin.2011.03.001","article-title":"Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations","volume":"4","author":"Angiolillo","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2011.05.016_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00365518109097495","article-title":"Filterability and pharmacology","volume":"156","author":"Lecomte","year":"1981","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"10.1016\/j.jcin.2011.05.016_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1185\/03007997709109338","article-title":"The effect of oxpentifylline (\u2018Trental\u2019) on fibrinolytic activity and plasma fibrinogen levels","volume":"4","author":"Jarrett","year":"1977","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcin.2011.05.016_bib34","first-page":"331","article-title":"The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease","volume":"10","author":"Ehrly","year":"1979","journal-title":"J Med"},{"key":"10.1016\/j.jcin.2011.05.016_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1025568714217","article-title":"Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin","volume":"252","author":"Abdollahi","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jcin.2011.05.016_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0006-2952(94)90477-4","article-title":"Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation","volume":"47","author":"Meskini","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jcin.2011.05.016_bib37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","article-title":"Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A- and phosphatidylinositol 3-kinase\/Akt-dependent mechanism","volume":"189","author":"Hashimoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcin.2011.05.016_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1592\/phco.29.5.526","article-title":"Pharmacologic therapy for intermittent claudication","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcin.2011.05.016_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11537670-000000000-00000","article-title":"Platelet P2Y12 receptor inhibition: an update on clinical drug development","volume":"10","author":"Vivas","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jcin.2011.05.016_bib40","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2011.05.016_bib41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2011.05.016_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/clpt.1985.6","article-title":"Kinetics of intravenous and oral pentoxifylline in healthy subjects","volume":"37","author":"Beermann","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2011.05.016_bib43","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2011.05.016_bib44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ahj.2009.10.008","article-title":"Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group","volume":"158","author":"Rao","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2011.05.016_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879811004201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879811004201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:57:19Z","timestamp":1761847039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879811004201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1936879811004201"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2011.05.016","relation":{},"ISSN":["1936-8798"],"issn-type":[{"type":"print","value":"1936-8798"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2011.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}